May 13, 2021 07:10 AM EDT
R&D

Am­gen, As­traZeneca bol­ster their case for break­through asth­ma pro­gram as FDA con­sid­ers tak­ing up a re­view

Max Gelman

Senior Editor

Just a few days af­ter sub­mit­ting a BLA for their high­ly-tout­ed asth­ma pro­gram, Am­gen and As­traZeneca re­leased new da­ta they hope will con­tin­ue to strength­en …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times